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Background: Previously, we found that treatment of LM8 murine osteosarcoma cells with genistein, an isoflavone
found in soy, increased the cellular level of β-catenin and decreased its invasive and motile potential. The purpose
of this study is to investigate whether the expression of β-catenin in LM8 cells is associated with metastatic
potential in nude mice. To this end, we used untreated and genistein-treated LM8 cells.
Methods: LM8 cells were treated for 3 days with or without 50 μM genistein and harvested by trypsinization.
Untreated (the control group) and genistein-treated (the genistein group) cells were subcutaneously inoculated into
the backs of male nude mice. After 25 days of inoculation, the tumors, lungs, and livers were excised, fixed in 10%
formalin, and embedded in paraffin. The sections of formalin-fixed, paraffin-embedded lungs and livers were stained
with hematoxylin-eosin (H&E) to confirm the absence or presence of metastatic tumors. The expression of β-catenin
within the primary tumor was immunohistochemically examined.
Results: All mice in the control group (n = 8) exhibited large primary tumors, while in the genistein group (n = 8),
one mouse showed no tumor formation and the remaining seven mice exhibited smaller primary tumors
compared with the control group. The tumor mass of the genistein group was 23% of that of the control group. In
the control group, multiple metastatic tumors were found in the lung and/or liver and the metastatic incidence
was 100% in the lung and 87.5% in the liver. Six of seven tumor-bearing mice in the genistein group developed no
metastatic tumors in the lung or liver, and this group was termed the genistein/metastasis(−) subgroup. Positive
β-catenin immunostaining was observed in the cytoplasm of tumor cells, and the β-catenin-labeling index was
higher in the genistein/metastasis(−) subgroup than in the control group. The intensity of cytoplasmic β-catenin
immunostaining was stronger in the genistein/metastasis(−) subgroup compared with the control group, and the
β-catenin-labeling score was 1.9-times higher in the former subgroup than in the latter group.
Conclusions: Overexpression of cytoplasmic β-catenin in LM8 cells causes inhibition of the growth of primary
tumors and loss of the metastatic potential to the lung and liver.
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Figure 1 The expression of β-catenin in untreated and
genistein-treated LM8 cells. LM8 cells were treated for 3 days
without (a) or with (b) 50 μM genistein, and immunohistochemical
staining of β-catenin was performed. Gen-treated cells are genistein-
treated LM8 cells. Magnification: ×40.
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Osteosarcoma is the most common malignant musculo-
skeletal tumor and occurs mainly in the metaphyseal re-
gion of long bones in young people [1,2]. Osteosarcoma
expands into the cortex of the bone, later erupts through
the cortex into the soft tissues, and often leads to the de-
velopment of micrometastases in the lung prior to diag-
nosis. The primary treatment of osteosarcoma is the
complete removal of tumor by wide excision with neo-
adjuvant and adjuvant chemotherapy [3]. Recently, Spina
et al. [4] reported that combination chemotherapy with
conventional chemotherapeutic drugs and compounds
that increase the therapeutic index of the drug may be
useful for the treatment of osteosarcoma. Despite pro-
gress in chemotherapy, however, the development of
metastatic tumors in the lung often has a fatal outcome
[2,5,6]. Therefore, the determination of a possible diag-
nostic marker for metastatic potential of primary tumor
cells is critical for the improvement of prognosis in pa-
tients with osteosarcoma.
The initial step of metastasis is cell detachment from
the primary tumor. It is well known that mutual adhe-
siveness of tumor cells is decreased compared with the
corresponding normal cells [7]. Cell-cell adhesion mole-
cules, such as catenins and cadherins, play a pivotal role
in the maintenance of cell-cell adhesion and normal tis-
sue architecture. β-Catenin is a cytoplasmic molecule,
interacts with the cytoplasmic domain of cadherins, and
supports the adhesion capability of cadherins [7]. Previ-
ously, we identified the loss of membranous β-catenin in
LM8 murine osteosarcoma cells [8], which possess ex-
tremely high metastatic potential to the lung [9-12].
Hugh et al. [13] reported that loss of membranous β-
catenin occurred commonly in primary colorectal can-
cers with metastatic potential and in the corresponding
colorectal liver metastases. Thus, loss of β-catenin at the
cell surface seems to be associated with tumor metasta-
sis. However, the association of the level of cytoplasmic
β-catenin with the metastatic potential of tumor cells re-
mains unclear.
Genistein is an isoflavone found in dried and green
soybeans and soy products, such as soy sauce, miso (fer-
mented soybean paste), and tofu (soybean curd). Experi-
mental studies have shown that genistein inhibits the
growth, invasion, and metastasis of tumors in vivo and
in vitro [8,14-16]. Previously, we found that treatment of
LM8 cells with genistein inhibited cell proliferation, de-
creased the expression and secretion of matrix metallo-
proteinase 2 (MMP-2), which plays a pivotal role in
tumor growth, invasion and metastasis [17-19], and de-
creased cell invasive and motile potential [8]. Moreover,
this treatment induced morphological changes, markedly
decreased the formation of multilayer masses, and in-
creased the level of osteocalcin mRNA [8]. Thus,genistein may induce the differentiation of LM8 cells.
These findings raise the question of whether genistein-
treated LM8 cells have the potential to metastasize to
the lung in vivo.
To explore the above question, untreated and genistein-
treated LM8 cells were subcutaneously inoculated into the
backs of nude mice, and whether they developed meta-
static tumors in the lung was histochemically examined.
The main purpose of this study is to investigate the associ-
ation of the expression of cytoplasmic β-catenin in pri-
mary tumor cells with metastatic potential. Therefore, the
expression of β-catenin within the primary tumor was
immunohistochemically examined. In addition, whether
the metastatic potential of primary tumor cells is associ-
ated with the expression of MMP-2 was also examined.
Results
The expression of β-catenin in untreated and genistein-
treated LM8 cells
LM8 cells were treated for 3 days without or with 50 μM
genistein and fixed with ethanol. The expression of
β-catenin in untreated and genistein-treated LM8 cells
was immunohistochemically examined. In untreated LM8
cells, positive β-catenin immunostaining was observed
in the cytoplasm and/or nucleus, and the intensity of
immunostaining in the cytoplasm was weak (Figure 1a).
In genistein-treated LM8 cells, positive β-catenin immu-
nostaining was predominantly observed in the cytoplasm,
and the intensity of immunostaining was stronger than
that observed in untreated LM8 cells (Figure 1b). These
findings indicate that genistein-treated LM8 cells expressed
higher levels of cytoplasmic β-catenin than untreated
LM8 cells.
Growth and metastasis of untreated and genistein-
treated LM8 cells in nude mice and C3H mice
Untreated and genistein-treated LM8 cells were har-
vested by trypsinization, centrifuged, resuspended in
Table 1 Engraftment rate and metastatic incidence of the






Control group 8/8 (100%) 8/8 (100%)* 7/8 (87.5%)*
Genistein group 7/8 (87.5%) 0/7 (0%)* 1/7 (14.3%)*
C3H mice
Control group 7/7 (100%) 7/7 (100%)§ 4/7 (57.1%)§
Genistein group 0/7 (0%) 0/7 (0%)§ 0/7 (0%)§
*The sections of formalin-fixed, paraffin-embedded lungs and livers were
stained with H&E, and metastatic tumors were microscopically confirmed.
§Multiple metastatic nodules at the surface of lungs and livers were
macroscopically confirmed using a magnifying glass.
Kidani et al. Cancer Cell International 2014, 14:31 Page 3 of 9
http://www.cancerci.com/content/14/1/31genistein-free culture medium, and inoculated subcuta-
neously into the backs of nude mice. Mice inoculated
with untreated LM8 cells were termed the control group
and those inoculated with genistein-treated LM8 cells
were termed the genistein group. In the control group,
all mice exhibited large tumors measuring 1.6-3.0 cm at
the inoculation site (Figure 2A-a). The engraftment rate
of tumor cells, which was calculated by dividing the
number of tumor-bearing mice by the total number of
mice, was 100% (Table 1). In the genistein group, one
mouse did not exhibit tumors at the inoculation site and
the remaining seven mice exhibited smaller tumors
measuring 0.6-1.6 cm compared with the control group
(Figure 2A-b). The engraftment rate of tumor cells wasFigure 2 Growth of LM8 cells in the control and genistein groups. (A) Appearance of the inoculation site of the control (a, c) and genistein
(b, d) groups. (a, b) nude mice at 25 days after tumor inoculation. (c, d) C3H mice at 36 days after tumor inoculation. (B) At 25 days after tumor
inoculation into the backs of nude mice, tumor weight was measured. Values given are the means ± SE for eight mice in the control group and
for seven mice in the genistein group. *p < 0.05 (compared with the control group) (C) At 25 days after tumor inoculation into the backs of nude
mice, body weight was measured after the excision of the tumor. Values given are the means ± SE for eight mice in both groups. **p < 0.01
(compared with the control group) (D) Correlation between body weight and tumor weight in nude mice (n = 16) is shown. (●) the control
group; (○) the genistein group.
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the control group and 0.89 ± 0.16 g in the genistein group
(p < 0.05) (Figure 2B), indicating that genistein-treated
LM8 cells grew at lower growth rate compared with un-
treated LM8 cells. The body weight was 19.5 ± 1.0 g in the
control group (n = 8), and 24.0 ± 0.7 g in the genistein
group (n = 8; p < 0.01) (Figure 2C). The body weight
correlated negatively with the tumor weight [r = −0.812
(n = 16), p < 0.0001] (Figure 2D). Thus, the body weight
decreased with the growth of the primary tumor.
To examine the presence of metastatic tumors in nude
mice, the sections of formalin-fixed, paraffin-embedded
lungs and livers were stained with H&E and observed
microscopically under low magnification (×4). In the
control group, multiple metastatic tumors were found in
the lung (Figure 3a) and liver (Figure 3b) and the meta-
static incidence was 100% in the lung and 87.5% in the
liver (Table 1). In the genistein group, one exhibited the
presence of the metastatic tumor in the liver (Figure 3d),
but not the lung (Figure 3c). The remaining six mice did
not exhibit the presence of any metastatic tumors in the
lung (Figure 3e) or liver (Figure 3f ), and this group was
termed the genistein/metastasis(−) subgroup. The meta-
static incidence in the genistein group was 0% in the
lung and 14.3% in the liver (Table 1).
In another series of experiments, untreated and
genistein-treated LM8 cells were subcutaneously inocu-
lated into the backs of C3H mice. In the control group
(n = 7), all mice exhibited large tumors measuring
0.7-1.7 cm at the inoculation site (Figure 2A-c). The en-
graftment rate of tumor cells was 100% (Table 1). The
tumor weight of this group was 1.17 ± 0.20 g. MultipleFigure 3 Existence of metastatic tumors in the lung and liver. The sec
(b, d, f) were stained with H&E. Arrows: metastatic tumor. (a, b) the contrometastatic nodules were macroscopically identified at the
surface of the lung and liver (data not shown), and the
metastatic incidence was 100% in the lung and 57.1% in
the liver (Table 1). In the genistein group (n = 7), no mice
exhibited any tumors at the inoculation site (Figure 2A-d)
and developed metastatic nodules at the surface of the
lung and liver (data not shown). Both the engraftment rate
of tumor cells and metastatic incidence were 0% (Table 1).
Expression of β-catenin within the primary and metastatic
tumors in nude mice
The expression of β-catenin within the primary tumors
was immunohistochemically examined. Positive β-catenin
immunostaining was predominantly observed in the
cytoplasm of tumor cells (Figure 4A-a and 4A-c). In the
control group, β-catenin-positive cells were sparsely ob-
served within the primary tumor (Figure 4A-b), and the
β-catenin-labeling index was 47 ± 6% (n = 8) (Figure 4C).
Since the intensity of immunostaining varied significantly,
the β-catenin-labeling score was also evaluated. The
β-catenin-labeling score in the control group was 73 ± 10
(n = 8) (Figure 4D). In the genistein/metastasis(−) sub-
group, β-catenin-positive cells were extensively observed
within the primary tumor (Figure 4A-d), and the intensity
of immunostaining was stronger compared with the
control group (Figure 4A-c). The labeling index [82 ± 3%
(n = 6)] and labeling score [140 ± 8 (n = 6)] for β-catenin
were higher (p < 0.01) than those of the control group
(Figure 4C and 4D).
The metastatic tumors in the lung (Figure 4B-e) and
liver (Figure 4B-f ) also expressed β-catenin in the cyto-
plasm, but the intensity of immunostaining was weaktions of formalin-fixed, paraffin-embedded lung (a, c, e) and liver
l group. (c-f) the genistein group. Magnification: ×4.
Figure 4 Expression of β-catenin in the primary and metastatic tumors. (A) Immunohistochemistry for β-catenin was performed using the
primary tumor sections. (a, b) the control group. (c, d) Gen/meta(−) subgroup is the genistein/metastasis(−) subgroup. Magnification: (a, c) × 40;
(b, d) × 4. (B) Immunohistochemistry for β-catenin was performed using the sections of the lung (e) and liver (f) in the control group. Magnification:
×40. (C and D) The β-catenin-labeling index (C) and β-catenin-labeling score (D) were determined. Gen/meta(−) subgroup is the genistein/metastasis(−)
subgroup. Values given are the means ± SE for eight tumor specimens in the control group and for six tumor specimens in the genistein/metastasis(−)
subgroup.
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tumor were strongly immunostained.
Expression of MMP-2 within the primary tumor in nude mice
The expression of MMP-2 within the primary tumor
was immunohistochemically examined. Positive MMP-2
immunostaining was observed in the cytoplasm of tumor
cells (Figure 5A-a and 5A-c). In the control group, MMP-
2-positive cells were extensively observed within the
primary tumor (Figure 5A-b), and the MMP-2-labeling
index was 48 ± 2% (n = 8) (Figure 5B). In the genistein/
metastasis(−) subgroup, the primary tumor contained
fewer MMP-2-positive cells compared with the control
group (Figure 5A-d), and the MMP-2-labeling index [20 ±
5% (n = 6)] was lower (p < 0.01) than that of the control
group (Figure 5B).
Discussion
The purpose of this study was to investigate in vivo
whether the level of cytoplasmic β-catenin in LM8 cells af-
fected metastatic potential. To this end, we first examinedwhether untreated and genistein-treated LM8 cells metas-
tasized to the distant organs in nude mice because
genistein-treated LM8 cells expressed higher levels of
cytoplasmic β-catenin than untreated LM8 cells (Figure 1).
In the control group, primary tumor cells formed meta-
static lesions in the lung and/or liver of all nude mice
(Table 1). This is compatible with the previous reports
stating that LM8 cells show an extremely high incidence
of pulmonary metastasis in mice [9-12]. In the genistein
group, primary tumor cells did not form metastatic le-
sions in the lung of all nude mice and the liver of 85.7%
of nude mice (Table 1). This finding indicates that a
majority of primary tumor cells in the genistein group
lost metastatic potential.
Next, we performed immunohistochemical staining of
β-catenin within the primary tumor. In the control
group, 53% of tumor cells within the primary tumor
were β-catenin-negative (Figure 4C), and the remaining
47% were β-catenin-positive but the intensity of immu-
nostaining was weak or intermediate (Figure 4A-a).
In the genistein/metastasis(−) subgroup, 82% of tumor
Figure 5 Expression of MMP-2 in the primary tumors. (A) Immunohistochemistry for MMP-2 was performed using the primary tumor sections.
(a, b) the control group. (c, d) Gen/meta(−) subgroup is the genistein/metastasis(−) subgroup. Magnification: (a, c) × 40; (b, d) × 4. (B) The MMP-
2-labeling index was determined. Gen/meta(−) subgroup is the genistein/metastasis(−) subgroup. Values given are the means ± SE for eight
tumor specimens in the control group and for six tumor specimens in the genistein/metastasis(−) subgroup.
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(Figure 4C) and the intensity of immunostaining was
stronger compared with the control group (Figure 4A-c).
The results of β-catenin-labeling score showed that
primary tumor cells in the genistein/metastasis(−) sub-
group contained 1.9-times higher level of cytoplasmic
β-catenin than those in the control group (Figure 4D).
Based on these findings, we concluded that overexpres-
sion of cytoplasmic β-catenin in LM8 cells caused loss
of metastatic potential to the lung and liver. Kashima
et al. introduced N-cadherin and cadherin-11 cDNAs
into LM8 cells, in which there was little endogenous ex-
pression of these two cadherins, to investigate the role
of the cadherins in osteosarcoma metastasis in vivo [20].
They found that the primary tumor of C3H mice
injected with cadherin-transfected LM8 cells contained
higher levels of cadherins compared with those injected
with control, empty vector-transfected LM8 cells and
that a high number of metastatic lesions were present in
the lung of the latter mice, whereas there was a marked
reduction in pulmonary metastases in the former mice.
Based on these findings, they concluded that overexpres-
sion of cadherins attenuated the ability of LM8 cells to
form pulmonary metastases.
Asai et al. [9] reported that subcutaneous inoculation
of LM8 cells into the backs of C3H mice caused the
rapid growth of tumor cells at the inoculation site and
the formation of multiple metastatic nodules at the
surface of the lung, and both the engraftment rate
of tumor cells and metastatic incidence were 100%.
The present study confirms this (Table 1). However,
genistein-treated LM8 cells inoculated into the backs of
C3H mice did not grow at the inoculation site and didnot form metastatic nodules at the surface of the lung
and liver (Table 1). Even in nude mice, the engraftment
rate of the genistein group did not reach 100% (Table 1).
Moreover, the metastatic incidence of this group was
only 14.3%. These findings indicate that the malignancy
of genistein-treated LM8 cells may be low. Since a
majority of primary tumor cells in the genistein group
was β-catenin-positive (Figure 4C), the present findings
suggest that high expression of β-catenin within the
primary tumor is associated with low malignancy of
tumor cells. In human endometrial carcinoma, positive
β-catenin expression has been reported to be associated
with decreases in the stage and grade of the tumor
[21,22]. Athanassiadou et al. [21] reported that loss of
β-catenin is a strong and independent predictor of an
unfavorable outcome in patients with endometrial car-
cinoma. In human gastric cancer, decreased expression
of E-cadherin and catenins, including β-catenin, corre-
lated with poor differentiation [23,24].
Invasion of tumor cells into the basement membrane
is a critical event for tumor metastasis. Invasive tumors
exhibit high levels of MMPs [8,9,12,17]. MMPs are cap-
able of digesting various components of the extracellular
matrix (ECM) and play a pivotal role in tumor metasta-
sis by removing physical barriers to invasion [18,19]. In
particular, MMP-2 degrades ECM macromolecules in
the basement membranes and other interstitial connect-
ive tissues [18]. Asai et al. [9] reported that LM8 cells se-
creted higher levels of MMP-2 and exhibited extremely
higher invasiveness in vitro compared with Dunn murine
osteosarcoma cells with no metastatic potential to the
lung. Our previous in vitro study showed that genistein-
treated LM8 cells secreted lower levels of MMP-2 and
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[8]. Moreover, our previous study with nude mice inocu-
lated with LM8 cells showed that decreased expression
of MMP-2 within the primary tumor was associated
with the suppression of the development of metastasis
in the lung [12]. Our present study showed that a major-
ity of primary tumor cells of the genistein/metastasis(−)
subgroup was MMP-2-negative (Figure 5A-c). The per-
centage of MMP-2-negative cells to total cells in this
subgroup was 80 ± 5% (Figure 5B). This value was
similar to that of the β-catenin-labeling index (82 ± 3%)
in this subgroup. Taken together, our present findings
suggest that decreased expression of MMP-2 in β-
catenin-overexpressing LM8 cells may cause the pre-
vention of local invasion, thus resulting in inhibition of
the growth of primary tumor and the metastasis to the
lung and liver.
In this study, we performed heat-induced antigen re-
trieval in 10 mM citrate buffer (pH 6.0) for immunohisto-
chemical staining of β-catenin and showed that the
primary tumor in the control group expressed lower level
of cytoplasmic β-catenin compared with the genistein/
metastasis(−) subgroup (Figure 4A). Moreover, we found
that the metastatic tumor in the lung and liver also
expressed very low level of cytoplasmic β-catenin (Figure 4B).
Kashima et al. [25] also performed antigen retrieval in
citrate acid buffer and showed low expression of cyto-
plasmic β-catenin in human primary osteosarcoma
with metastasis and human metastatic osteosarcoma.
Thus, osteosarcoma with metastatic potential seems to
exhibit low expression of cytoplasmic β-catenin when
heat-induced antigen retrieval was performed under acidic
pH. Iwaya et al. [10] performed heat-induced antigen re-
trieval in 10 mM citrate buffer (pH 8.0) and showed that
the expression of cytoplasmic and/or nuclear β-catenin
within the primary tumor was higher in C3H mice in-
oculated with LM8 cells than in those inoculated with
Dunn cells. Moreover, they found that in human meta-
static osteosarcoma, more than 10% of tumor cells were
immunostained for β-catenin in the cytoplasm and/or
nucleus [10]. These findings are inconsistent with ours.
This inconsistency may be due to the different pH uti-
lized in heat-induced antigen retrieval because the effi-
ciency of heat-induced antigen retrieval is dependent
on the pH of the retrieval solutions [26-28].
Preclinical and clinical studies have shown that protein
kinases, which are involved in the regulation of a wide
variety of cellular processes, are relevant targets for can-
cer therapy [29,30]. Bruzzese et al. [31] reported that
treatment of Hep-2 cells with gefitinib, a tyrosine kinase
inhibitor [29], inhibited tyrosine phosphorylation of
epidermal growth factor receptor and decreased invasive
potential. Genistein also is a specific and potent inhibitor
of tyrosine kinase [32,33]. We previously found that genisteindecreased motile and invasive potential of LM8 cells
[8]. Whether genistein inhibited tyrosine phosphorylation
of proteins in LM8 cells remains unclear. It is unlikely,
however, that high expression of cytoplasmic β-catenin in
genistein-treated LM8 cells results from inhibition of tyro-
sine phosphorylation of β-catenin by genistein because
phosphorylation of β-catenin by tyrosine kinase leads to
an increase in the free pool of cytoplasmic β-catenin
during epithelial cell migration [34]. This interpretation
may be also supported by reports stating that tyrosine
phosphorylation of cell-cell adhesion molecules, includ-
ing β-catenin, affected their functions, causing unstable
cell-cell adhesion and migration of cells [35-37].
Conclusions
Overexpression of cytoplasmic β-catenin in LM8 cells
causes inhibition of the growth of primary tumors and
loss of metastatic potential to the lung and liver. There-
fore, overexpression of cytoplasmic β-catenin within the
primary osteosarcoma may indicate the absence of meta-
static lesions at distant organs when heat-induced anti-
gen retrieval for immunohistochemical staining was
performed under acidic pH.
Methods
Animals, cells, reagents, and antibodies
Male BALB/cA Jcl-nu nude mice (4-week-old) and male
C3H mice (4-week-old) were obtained from CLEA
Japan, Inc., Tokyo, Japan. LM8 cells (RBRC-RCB1450)
were obtained from RIKEN BRC Cell Bank, Ibaraki, Japan.
Genistein (Sigma-Aldrich, St. Louis, MO) was dissolved
in DMSO. For immunohistochemical staining, a rabbit
polyclonal antibody to β-catenin (sc-7199; Santa Cruz
Biotechnology, Santa Cruz, CA) and a mouse monoclo-
nal antibody to MMP-2 (NCL-MMP2-507; Novocastra
Reagent, Leica Microsystems, North Ryde, Australia) were
diluted to 1:100 and 1:80, respectively, with phosphate-
buffered saline (PBS).
Cell culture
LM8 cells (1.25 × 103 cells/cm2) were seeded on a
60 mm plate in culture medium, which contained 10%
fetal bovine serum, 100 units/ml penicillin, and 100 μg/
ml streptomycin in Dulbecco’s modified Eagle’s medium.
After 24 h of seeding, the medium was replaced with
culture medium with or without 50 μM genistein. Cells
were incubated for 3 days, harvested by trypsinization,
centrifuged at 1,000 × g for 10 min, and resuspended in
genistein-free culture medium for inoculation.
Tumor inoculation
The suspensions (1 × 105 cells/0.3 ml of culture medium)
of untreated and genistein-treated cells were subcutane-
ously inoculated into the backs of nude mice and C3H
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standard polypropylene mouse cage in a 12 h light–dark
cycle (lights on at 7 am and off at 7 pm) and were
allowed free access to laboratory chow and water.
After 25 (for nude mice) and 36 (for C3H mice) days of
inoculation, the animals were sacrificed under ether
anesthesia. In nude mice, the tumors, lungs, and livers
were excised, weighed, fixed in 10% formalin, and
embedded in paraffin. The sections (4 μm) of formalin-
fixed, paraffin-embedded lungs and livers were deparaffi-
nized, rehydrated, and stained with H&E to confirm
microscopically the absence or presence of metastatic
tumors. In C3H mice, the tumors were excised and
weighed. The lungs and livers were excised and observed
macroscopically using a magnifying glass to confirm the
absence or presence of metastatic nodules at the surface.
All animals were treated humanely, and care was taken
to alleviate suffering. The experimental protocols were
reviewed and approved by the local Animal Ethics Com-
mittees at the Ehime University Graduate School of
Medicine, Ehime, Japan.
Immunohistochemical studies
The sections (4 μm) of formalin-fixed, paraffin-embedded
tumors, lungs, and livers were deparaffinized and rehy-
drated, which were followed by heat-induced (30 min at
98°C) antigen retrieval in 10 mM citrate buffer (pH 6.0)
for β-catenin, and in 1 mM EDTA solution (pH 8.0) for
MMP-2. The sections were incubated for 1 h with a
primary antibody and were then incubated for 1 h with
EnVision™+ DualLink (Dako Japan, Inc., Tokyo, Japan), as
described previously [11]. Positive cells were visualized by
adding 3,3′-diaminobenzidine tetrahydrochloride (DAB;
Dako Japan) to the sections. The nuclei were counter-
stained with hematoxylin.
To determine the labeling index for β-catenin and
MMP-2 and the labeling score for β-catenin, the tumor
sections were observed microscopically under high-power
magnification (×40), and three different microscopic fields
per section were photographed. Then, β-catenin-positive
or MMP-2-positive cells present in approximately 500
cells per photograph were counted. The labeling index
was evaluated by determining the percentage of the num-
ber of positive cells to the total number of cells. To deter-
mine the labeling score, β-catenin expression was
estimated “0” if negative, “1+” if week intensity, and “2+”
for intermediate or strong intensity, as described previ-
ously [38]. The β-catenin-labeling score was evaluated as
follows: β-catenin-labeling score = [(1 × number of “1+”
cells + 2 × number of “2+” cells)/total number of cells] ×
100. The total number of cells is the sum of numbers of
“0”, “1+”, and “2+” cells. Values for three fields per tumor
section were averaged to obtain the labeling index and la-
beling score for each tumor.In another series of experiments, LM8 cells (1.19 ×
103 cells/cm2) were incubated for 24 h on a 2-well
chamber slide (Nalge Nunc International, Osaka,
Japan). Then, cells were treated for 3 days without or
with 50 μM genistein, fixed in 70% ethanol for 30 min,
incubated in 100% ethanol for 10 min, washed twice
with PBS, and incubated for 1 h with a rabbit poly-
clonal antibody to β-catenin (1:15 dilution in PBS con-
taining 1% bovine serum albumin) followed by 1-h
incubation with EnVision™+ DualLink. Positive cells
were visualized by adding DAB. The nuclei were coun-
terstained with hematoxylin. Cells were then mounted
in glycergel (Dako Japan) for light microscopy analysis
(magnification: ×40).
Statistical analyses
Significant differences between two independent groups
were analyzed using Student’s t-test. Pearson’s r was used
to calculate the correlation between the body weight and
the tumor weight. For all statistical analyses, the criterion
for significance was p < 0.05. All values were expressed as
the means ± SE.
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